Sign In

Ayman AlAbdallah

Venture Capital Investor

Ayman AlAbdallah is a Partner at Mubadala Capital, based in San Francisco, California.1 He focuses on early and growth-stage investments in healthcare technology, biotechnology, and deep tech companies.2 AlAbdallah joined Mubadala Capital in 2018 as part of the initial team launching the firm's venture capital business in San Francisco.2

Some key points about Ayman AlAbdallah:

  1. Investment focus: He specializes in the convergence of AI and drug discovery/development, partnering with companies from formation through growth and public rounds.2

  2. Board positions: AlAbdallah serves as a director or observer on the boards of numerous emerging biotechnology companies, including Iambic AI, Juvena Therapeutics, Unlearn AI, Vevo Therapeutics, and Xilis.2

  3. Notable investments: He has backed companies such as Exscientia (EXAI), Neumora (NMRA), Recursion (RXRX), Vir Biotechnology (VIR), and Vividion (acquired by Bayer).2

  4. Professional background: Prior to Mubadala Capital, AlAbdallah's career included roles in corporate development and M&A (Tecan Group), management consulting (Accenture), and hedge fund investing (OMERS Capital).2

  5. Education: He completed his M.B.A. and mechanical engineering studies at the University of Toronto, where he received the Chalmers Award and a fellowship for his engineering research thesis on Lab-on-a-Chip platforms.2

Regarding Iambic Therapeutics specifically, AlAbdallah led Mubadala Capital's investment in the company's $50 million Series B extension in 2024.3 He expressed enthusiasm for Iambic's AI-driven drug discovery platform and its potential to deliver differentiated drugs to the clinic rapidly.3

Highlights

Jul 25 · linkedin

Thank you Meagan Parrish and PharmaVoice for the thought-provoking conversation. In today's dynamic market, where groundbreaking innovations continue to emerge at an extraordinary pace, maintaining a long-term view and staying focused on creating value distinguishes companies and investors.

Biotech and healthcare are shining examples of the power of human ingenuity in tackling significant challenges. Even amid market fluctuations, it's inspiring to see founders and teams continue to push the boundaries of science and technology to tackle industry-wide bottlenecks and challenges to make lasting impact.

The future of biotech and healthcare – and many other sectors – is being shaped by visionaries who dare to think big and persevere through challenges. These innovators execute with precision while staying grounded in strong fundamentals, driving transformative change even in uncertain times. I'm grateful to the exceptional founders and teams I work with who inspire me daily as they work to drive progress and change our world for the better.

Mar 14 · linkedin

The outdated technology infrastructure that supports the staggering $4 trillion spent on healthcare in the US is reaching a breaking point. This was recently demonstrated by the unprecedented ransomware attack on Change Healthcare, which led to weeks of operational and financial disruptions for hospitals, physician offices, pharmacies, insurers, and patients. These disruptions led to around $100 million in estimated daily losses to healthcare providers, and $22 million paid to hackers.

Rolling out modern, transparent, and cost-effective enterprise health platforms has now become a priority. At Mubadala Capital, we’re thrilled to be on the journey of revolutionizing Pharmacy Benefit Managers with Capital Rx. Capital Rx is setting a new industry standard in how drugs are priced and patients are serviced through JUDI, their unmatched electronic claims processing platform. JUDI unifies and streamlines hundreds of tasks within a single modern and secure tech stack, provides unparalleled transparency into the pharmacy value chain, and aligns incentives between stakeholders.

I’m excited to see Capital Rx achieve yet another significant milestone by partnering with Prime Therapeutics to elevate the healthcare experience for tens of millions of patients. Congratulations to  A. J. Loiacono and Mostafa Kamal on the groundbreaking partnership. Changing large, antiquated systems is incredibly difficult, especially when people's lives depend on it, and I’ve been inspired by the work the Capital Rx team has done to challenge the status quo by combining decades of expertise with innovative technology.

This partnership brings us one step closer to a healthcare system that serves the needs of every patient, and I’m honored to be on this journey with you.

https://lnkd.in/dMEgd_jb

#healthtech #healthcare #technology #healthcare #pharmacy #drugpricing #pbms

Related Questions

What are Ayman AlAbdallah's key investments in the biotech sector?
How did Ayman AlAbdallah transition from consulting to investing?
What is Ayman AlAbdallah's role at Mubadala Capital?
Can you provide examples of Ayman AlAbdallah's most successful investments?
How does Ayman AlAbdallah contribute to the boards of companies like Iambic Therapeutics?
Ayman AlAbdallah
Ayman AlAbdallah, photo 1
Ayman AlAbdallah, photo 2
Add to my network

Location

San Francisco, California, United States